NASDAQ$VERA
Vera Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Vera Therapeutics reported Q1 2026 with no product revenue and a net loss of $121.0M ($1.69 per share) on atacicept development.
Vera had no commercial revenue in Q1 2026. Total operating expenses were $125.1 million (R&D $86.0M, G&A $39.1M), up from $57.2 million. Net loss was $121.0 million ($1.69 per share) versus $51.7 million as Phase 3 atacicept programs advanced. Cash strengthened after a December 2025 follow-on offering.
- Operating expenses $125.1M (+119%).
- Net loss $(121.0)M; EPS $(1.69).
- R&D $86.0M on atacicept Phase 3.
- Follow-on raised ~$281M net in Dec 2025.
- Pre-commercial IgA nephropathy focus.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$362K
Forward guidance
MD&A focuses on ORIGIN Phase 3 readouts, regulatory path, and cash runway rather than revenue guidance.
Tailwinds
- Strong cash post follow-on offering.
- Lead asset in late-stage development.
Headwinds
- Rapidly rising R&D spend.
- No near-term product revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro